General Information of Drug (ID: DMGECIJ)

Drug Name
Blinatumomab Drug Info
Synonyms AMG 103; Blincyto
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [1]
B-cell acute lymphoblastic leukaemia 2B33.3 Approved [2]
Diffuse large B-cell lymphoma 2A81 Phase 2/3 [3]
Cross-matching ID
TTD Drug ID
DMGECIJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tisagenlecleucel DMM9BJD Acute lymphoblastic leukaemia 2A85 Approved [5]
Axicabtagene ciloleucel DMYHN59 Diffuse large B-cell lymphoma 2A81 Approved [6]
Lisocabtagene maraleucel DMP45ME Large B-cell lymphoma 2A81 Approved [7]
Inebilizumab DMI0RHA Neuromyelitis optica spectrum disorder 8E4A.0 Approved [8]
Tecartus DMYQCWT Mantle cell lymphoma 2A85.5 Approved [9]
Loncastuximab tesirine DMXSVGI Diffuse large B-cell lymphoma 2A81 Approved [10]
Obexelimab DMVIC4J IgG4 related disease 4A43.0 Phase 3 [11]
MOR-208 DMDQOWT Diffuse large B-cell lymphoma 2A81 Phase 2/3 [12]
CART-19 DMST3FM Acute lymphoblastic leukaemia 2A85 Phase 2/3 [13]
CD19 CAR T cells DM32148 Acute lymphoblastic leukaemia 2A85 Phase 2/3 [14]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Mosunetuzumab DM15ZIB Follicular lymphoma 2A80 Approved [15]
Epcoritamab DMEX86V Diffuse large B-cell lymphoma 2A81 Approved [16]
Talquetamab DMXRENI Multiple myeloma 2A83 Approved [17]
Elranatamab DMG1MW2 Multiple myeloma 2A83 Approved [18]
Nivatrotamab DMAOUZV Small-cell lung cancer 2C25.Y Phase 2 [19]
Otelixizumab DMFNDBC Type-1 diabetes 5A10 Phase 2 [20]
Plamotamab DMOV28A Diffuse large B-cell lymphoma 2A81 Phase 2 [21]
Odronextamab DMP6NVV B-cell non-hodgkin lymphoma 2B33.5 Phase 2 [22]
Tarlatamab DME33OU Small-cell lung cancer 2C25.Y Phase 2 [23]
TAK-280 DM08RE5 Aggressive cancer 2A00-2F9Z Phase 2 [24]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN Modulator [4]
T-cell surface glycoprotein CD3 (CD3) TTUN7MC NOUNIPROTAC Modulator [4]

References

1 ClinicalTrials.gov (NCT02013167) Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
2 Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies. Hum Vaccin Immunother. 2019;15(3):594-602.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
5 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
10 Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
11 Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
12 A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
13 ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
14 ClinicalTrials.gov (NCT03391726) CART-19 Cells for R/R B-cell Lymphoma
15 Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
16 Clinical pipeline report, company report or official report of Genmab.
17 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
18 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
19 Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
20 Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
21 Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
22 Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
23 Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.
24 ClinicalTrials.gov (NCT05220098) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer. U.S.National Institutes of Health.